{"id":649,"date":"2020-11-20T09:29:06","date_gmt":"2020-11-20T09:29:06","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=649"},"modified":"2020-11-20T09:29:06","modified_gmt":"2020-11-20T09:29:06","slug":"13-nov-2020-tocilizumab-beneficial-in-covid-19-cytokine-storm","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/13-nov-2020-tocilizumab-beneficial-in-covid-19-cytokine-storm\/","title":{"rendered":"(13 Nov 2020) Tocilizumab- beneficial in COVID-19 cytokine storm"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Treatment with Tocilizumab for Patients with Covid-19 Infections: A Case-series Study<\/p>\n<p>https:\/\/doi.org\/10.1002\/jcph.1787<\/p>\n<p class=\"\">This retrospective, observational study included 38 patients with an average age of 63 years (IQR: 48-70). The average dose of TCZ given was 519 +\/- 61 mg. The median values of C-reactive protein (CRP) significantly decreased following TCZ administration (189.9 vs. 54.8 mg\/L, p = 0.003). Nineteen (73 %) of all febrile patients before the initiation of TCZ became fever free on the fourth day of TCZ treatment. Following TCZ treatment, 11 patients developed infections due to multidrug-resistant bacteria, and elevated liver transaminases were observed in 6 patients. The preliminary findings of this study suggested TCZ appeared to ameliorate COVID-19-related cytokine storm syndrome.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Treatment with Tocilizumab for Patients with Covid-19 Infections: A Case-series Study https:\/\/doi.org\/10.1002\/jcph.1787 This retrospective, observational study included 38 patients with an average age of 63 years (IQR: 48-70). The average dose of TCZ given was 519 +\/- 61 mg. The&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/13-nov-2020-tocilizumab-beneficial-in-covid-19-cytokine-storm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(13 Nov 2020) Tocilizumab- beneficial in COVID-19 cytokine storm&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/649"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=649"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/649\/revisions"}],"predecessor-version":[{"id":650,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/649\/revisions\/650"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}